Upgrades

Solid order-book underpins growth as execution accelerates About the stock: Hindustan Aeronautics (HAL), one of the largest Defence PSU in India, is engaged in design, development, manufacture, repair, overhaul, upgrade...

Well poised to see significant recovery in explosives & exports/overseas segment: With market leading share of ~25% in domestic industrial explosives market, we believe that company is well poised to grow steadily led by healthy demand prospects from segments like mining, housing and infrastructure. Though domestic explosives segment remained muted during the quarter, we expect recovery going ahead led by healthy demand from housing, infra and mining sectors. With an order backlog of 1600+ crore in explosives and stable raw material prices, we expect ~14%...

Bosch’s(BOS) 2QFY26 PAT at INR5.5b was in line with our estimates. The mobility business was the key growth driver in 2Q, having posted 14% YoY growth, while the non-mobility segment posted a 17% decline.

TPWR’s consolidated EBITDA/adj. PAT came in at INR33b/INR9.2b, below our estimates by 12%/13%. The weakness in results was largely attributable to Mundra plant shutdown in 2Q, which offset the stronger performance at Odisha distribution and the solid ramp-up at TP Solar on a YoY basis.

Divi’s Laboratories’ (Divi’s) Q2FY26 result was in line with our expectations on all fronts. Constant currency growth slowed down to ~10.8% vs. 15% QoQ and 18% in FY25.

Torrent Pharma (TRP) delivered in-line financial performance for the quarter. YoY growth improved in the US generics and LATAM markets, led by new product launches and steady market share gains in the base portfolio.

Divi’s Laboratories (DIVI) delivered better-than-expected performance in 2Q with a 4%/10%/10% beat on revenue/EBITDA/PAT.

Cholamandalam Inv. & Finance (CIFC)’s 2QFY26 PAT grew ~20% YoY to INR11.5b (in line). PAT grew ~20% YoY in 1HFY26, and we expect its PAT to grow ~21% YoY in 2H.

Britannia Industries (BRIT) posted consolidated revenue growth of 4% YoY in 2QFY26 (below). Adjusted for the GST transition impact, sales growth would have been ~6-6.5% YoY, as the business faced short-term headwinds in September due to de-stocking.

Q2FY26 Performance: Revenue at US$ 1180.1 mn, was up 2.3% QoQ/4.7% YoY (up 2.4% QoQ CC/ 4.4% YoY CC). In rupee terms, revenue stood at 10,394 crore, up 5.6% QoQ and 10.2% YoY. EBIT margin expanded by ~160 bps QoQ to 15.9%. PAT...

Net interest income fell 0.5% YoY to Rs. 10,469cr, and consequently, net interest margin (NIM) shrank 30 basis points (bps) to 2.6%, owing to a drop in yield on advances to 7.9% (-40bps YoY) in Q2FY26. Pre-provision profit rose 5.5% YoY to Rs. 7,227cr in Q2FY26, fuelled by drop in...

Q2FY26 performance: IHCL consolidated revenues grew by 12% YoY to Rs.2,041cr. Hotel business revenues witnessed slower growth on account of factors such as high base, room innovation and intense rainfall in Q2FY26. Standalone room revenues decreased by 3% while F&B revenues grew by just 2% during the quarter. RevPAR stood at Rs.11000. Consolidated EBIDTA margins improved by 49bps YoY to 27.9%. EBIDTA grew by 14% YoY to Rs570.1cr. Overall PBT grew by 17%yoy to...

We maintain REDUCE on Britannia, with a Sep-26E TP of Rs5,750, on 48x P/E (in line with its last 5Y average forward P/E). Q2 net sales grew at ~4%, 1%/4% below our estimate/consensus expectation.

Ambuja Cements' standalone Q2FY26 results reflected strong operational momentum with revenue of Rs53bn, rising 20% YoY and 4% sequentially, supported by robust demand, improved realizations, and higher premium product contribution. Cement sales volumes stood at 8.8mn tonnes, growing 19% YoY and 3% QoQ. Operating EBITDA increased to Rs10bn, up 32% from Rs7.8bn a year ago and 6% from Rs9.7bn in the previous quarter, driven by lower fuel and power costs, and improved efficiency. EBITDA/t stood at Rs1,167 compared to Rs1,010 in Q1FY26 and Rs988 in Q2FY25. PAT rose sharply to...

We maintain our BUY rating on the stock.

With healthy volume growth and significant improvement in EBITDA/ton over FY25-28E, we expect revenue & EBITDA CAGR at ~13% & ~30% respectively over the same period. We maintain BUY on Ambuja Cements with a target price of Rs 700 (based on 17x EV/EBITDA on FY27E & FY28E...

Ambuja Cements (ACEM) reported strong growth of ~81% YoY in EBITDA to INR17.6b (~28% beat, led by lower-than-estimated opex/t).

We maintain our BUY recommendation on the stock, supported by its reasonable valuations.

BPCL’s EBITDA/PAT came in 32%/40% above expectationsin 2QFY26, driven by higher-than-anticipated GRM (USD10.8/bbl). Blended marketing margin also stood 35% above our estimate at INR7.2/lit (up 25% YoY).

Bank of Baroda reported a healthy performance in Q2 FY26, led by improved operating performance and pick-up in credit growth.